Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy

Aki Furusawa(University of Maryland, Baltimore), Arnob Banerjee(Johnson & Johnson (United States)), Haley Simpson(University of Maryland, Baltimore), John Reiser(University of Maryland, Baltimore), Kavitha Sadashivaiah(University of Maryland, Baltimore)
Journal of Immunotherapy
December 22, 2017
10.1097/cji.0000000000000206
Cited by 7

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
|Science|2007|852
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche
|The Journal of Immunology|2010|417